Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 11, 2001, Pages 1729-1736

  Edwards, S J ^a   Lind, T ^b   Lundell, L ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; HEALING; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; REVIEW;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; HUMANS; OMEPRAZOLE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0034783326     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01128.x     Document Type: Review

References (35)

1. Epidemiology of reflux disease and reflux oesophagitis
2. Reflux oesophagitis: Quantitative systematic review of the evidence of effectiveness of proton pump inhibitors and histamine antagonists
3. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
4. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
5. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
6. max of esomeprazole on acid secretion and intragastric pH
7. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis
8. Assessing the quality of reports of randomised controlled trials: Is blinding necessary?
9. Statistical aspects of the analysis of data from retrospective studies of disease
10. Meta-analysis in clinical trials
11. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
12. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
13. Double blind, placebo controlled comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of ersoive or ulcerative GORD
14. Rabeprazole is comparable to omeprazole in the healing of erosive GERD and provides more rapid heartburn relief
15. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis
16. Pantoprazole versus omeprazole in the treatment of reflux esophagitis
17. Comparison of omeprazole, lansoprazole and pantoprazole in the treatment of elderly patients with esophagitis
18. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux esophagitis
19. Lansoprazole versus omeprazole in the treatment of reflux oesophagitis
20. Efficacy and safety of lansoprazole in the treatment of reflux oesophagitis
21. Reflux oesophagitis: A comparative study of lansoprazole and omeprazole as short-term therapy
22. Pantoprazole versus omeprazole in acute reflux esophagitis
23. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
24. Pantoprazole and omeprazole in the treatment of reflux esophagitis
25. A double blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis
26. Efficacté compareé du lansoprazole et de l'oméprazole dans le traitement de l'oesophagite peptique
27. Lansoprazole in the acute treatment of reflux esophagitis
28. On a criterion that a given system of deviations from the probable in the case of a correlated system of variable is such that it can reasonably be supposed to have arisen in random sampling
29. Effect of omeprazole - A gastric proton pump inhibitor - On pentagastrin stimulated acid secretion in man
30. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - A prospective, randomized, multi-centre study
31. Strategies for medical management of reflux disease
32. Economic evaluation of long-term management strategies for erosive oesophagitis
33. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors